Human BCMA/TNFRSF17 enzyme-linked immunoassay kit
| Specification | 96 Test |
|---|---|
| Sensitivity | 0.45 pg/ml (50 μl)；1.52 pg/ml (10 μl) |
| Standard Curve Range | 6.86~5000 pg/ml |
| Standard Curve Gradient | 7 Points/3 Folds |
| Number of Incubations | 2 |
| Sample Volume | 50 μl/10 μl |
| Type | Fully Ready-to-Use |
| Operation Duration | 120min |
| pg/ml | O.D. | Average | Corrected | |
|---|---|---|---|---|
| 0.00 | 0.0088 | 0.0086 | 0.0087 | |
| 6.86 | 0.0244 | 0.0247 | 0.0246 | 0.0158 |
| 20.58 | 0.0611 | 0.0643 | 0.0627 | 0.0540 |
| 61.73 | 0.2083 | 0.2159 | 0.2121 | 0.2034 |
| 185.19 | 0.6262 | 0.6201 | 0.6232 | 0.6144 |
| 555.56 | 1.8500 | 1.9220 | 1.8860 | 1.8773 |
| 1666.67 | 3.2090 | 3.2870 | 3.2480 | 3.2393 |
| 5000.00 | 3.6870 | 3.6950 | 3.6910 | 3.6823 |
Precision
| Intra-assay Precision | Inter-assay Precision | |||||
| Sample Number | S1 | S2 | S3 | S1 | S2 | S3 |
| 22 | 22 | 22 | 6 | 6 | 6 | |
| Average(pg/ml) | 97.3 | 531.3 | 963.5 | 102.3 | 532.2 | 1496.3 |
| Standard Deviation | 3.7 | 26.4 | 17.4 | 1.9 | 16.1 | 28.5 |
| Coefficient of Variation(%) | 3.8 | 5.0 | 1.8 | 1.9 | 3.0 | 1.9 |
Intra-assay Precision (Precision within an assay) Three samples of known concentration were tested twenty times on one plate to assess intra-assay precision.
Inter-assay Precision (Precision between assays) Three samples of known concentration were tested six times on one plate to assess intra-assay precision.
Spike Recovery
The spike recovery was evaluated by spiking 3 levels of human BCMA/TNFRSF17 into health human serum sample. The un-spiked serum was used as blank in this experiment.
The recovery ranged from 84% to 106% with an overall mean recovery of 93%.
Sample Values
| Sample Matrix | Sample Evaluated | Range (pg/ml) | Detectable (%) | Mean of Detectable (pg/ml) |
|---|---|---|---|---|
| Serum | 30 | 1715.39-3905.61 | 100 | 2432.79 |
Serum/Plasma – Thirty samples from apparently healthy volunteers were evaluated for the presence of BCMA/TNFRSF17 in this assay. No medical histories were available for the donors.
Product Data Sheet
Background: BCMA/TNFRSF17
BCMA, B cell maturation antigen, is a member of the TNF receptor superfamily. It has been designated TNFRSF17. BCMA is a type III membrane protein containing one extracellular cysteine rich domain. Within the TNFRSF, it shares the highest homology with TACI. BCMA and TACI have both been shown to bind to APRIL and BAFF, members of the TNF ligand superfamily. BCMA expression has been found in immune organs and mature B cell lines. Although some expression has been observed at the cell surface, BCMA appears to be localized to the Golgi compartment. The binding of BCMA to APRIL or BAFF has been shown to stimulate IgM production in peripheral blood B cells and increase the survival of cultured B cells. This data suggests that BCMA may play an important role in B cell development, function and regulation. Human BCMA is a 184 amino acid (aa) protein consisting of a 54 aa extracellular domain, a 23 aa transmembrane domain, and a 107 aa intracellular domain. Mouse and human BCMA share 62% amino acid identity.
